Related Experiment Video
Updated: Jan 1, 2026
Adenoviral Transduction of Naive CD4 T Cells to Study Treg Differentiation
Published on: August 13, 2013
A novel method for efficient generation of antigen-specific effector T-cells using dendritic cells transduced with
Leonardo Mirandola1, Maurizio Chiriva-Internati2,3, Robert Bresalier4
1Kiromic, Inc, 7707 Fannin St., Suite 140, Houston, TX, 77054, USA.
Background:
The inefficacy of standard therapeutic strategies for ovarian cancer is reflected by the enduring poor prognosis of this malignancy. Due to the potential for exquisite specificity, sensitivity and long-term memory, immunotherapy offers an alternative modality for durable control of the disease, provided appropriate antigens can be identified and presented in the right context.
Methods:
We tested a novel dendritic cell vaccine formulation to reprogram autologous antigen-specific T-cells in vitro, in vivo in a murine model of ovarian cancer, and ex vivo using human cells from patients.
Results:
We show that dendritic cells (DCs) treated with a p38 MAPK inhibitor and transduced with a recombinant adenovirus associated vector (AAV) expressing Sperm protein (Sp) 17 are highly effective in generating antigen-specific T-cell cytotoxic response against ovarian cancer cells. Additionally, these DCs enhanced the differentiation of effector T-cells while reducing the frequency of Foxp3+ T-reg cells in vitro.
Conclusions:
This work provides a rationale for translation of pharmacologically reprogrammed DCs into clinical trials for prevention of tumor recurrence and progression in high-risk ovarian cancer patients.
Insights
A novel dendritic cell (DC) vaccine effectively reprograms T-cells to target ovarian cancer. This immunotherapy approach shows promise for preventing tumor recurrence and progression in high-risk patients.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Standard ovarian cancer treatments have limited efficacy, leading to poor patient prognosis.
- Immunotherapy offers potential for durable disease control by leveraging T-cell memory and specificity.
- Identifying and presenting appropriate antigens is crucial for successful immunotherapy.
Purpose of the Study:
- To develop and evaluate a novel dendritic cell (DC) vaccine formulation for ovarian cancer.
- To assess the vaccine's ability to reprogram autologous antigen-specific T-cells.
- To investigate the vaccine's efficacy in preclinical models and human cells.
Main Methods:
- Dendritic cells (DCs) were treated with a p38 MAPK inhibitor.
- DCs were transduced with a recombinant adenovirus associated vector (AAV) expressing Sperm protein (Sp) 17.
- The vaccine's effects were tested in vitro, in a murine ovarian cancer model, and ex vivo with human cells.
Main Results:
- The modified DCs generated a potent antigen-specific T-cell cytotoxic response against ovarian cancer cells.
- The vaccine enhanced effector T-cell differentiation.
- A reduction in the frequency of regulatory T-cells (T-regs) was observed.
Conclusions:
- Pharmacologically reprogrammed DCs demonstrate significant potential for treating ovarian cancer.
- This approach provides a rationale for clinical trials in high-risk ovarian cancer patients.
- The vaccine may aid in preventing tumor recurrence and progression.
